ORG Wealth Partners LLC Buys New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

ORG Wealth Partners LLC purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,252 shares of the biopharmaceutical company’s stock, valued at approximately $53,000.

Several other institutional investors have also added to or reduced their stakes in the business. Valeo Financial Advisors LLC bought a new position in TG Therapeutics in the 3rd quarter worth $239,000. Daymark Wealth Partners LLC increased its position in TG Therapeutics by 73.7% in the third quarter. Daymark Wealth Partners LLC now owns 40,811 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 17,311 shares in the last quarter. Handelsbanken Fonder AB raised its stake in shares of TG Therapeutics by 22.6% in the third quarter. Handelsbanken Fonder AB now owns 49,900 shares of the biopharmaceutical company’s stock worth $1,167,000 after buying an additional 9,200 shares during the period. SG Americas Securities LLC lifted its position in shares of TG Therapeutics by 181.9% during the 3rd quarter. SG Americas Securities LLC now owns 23,614 shares of the biopharmaceutical company’s stock valued at $552,000 after buying an additional 15,238 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of TG Therapeutics during the 2nd quarter valued at approximately $10,423,000. 58.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $49.00 price objective on shares of TG Therapeutics in a research report on Wednesday, September 18th. Finally, B. Riley upped their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.83.

TG Therapeutics Stock Up 7.6 %

Shares of TGTX stock opened at $24.57 on Wednesday. The company’s fifty day simple moving average is $22.95 and its two-hundred day simple moving average is $19.19. TG Therapeutics, Inc. has a 52 week low of $6.46 and a 52 week high of $26.41. The stock has a market cap of $3.80 billion, a P/E ratio of 106.83 and a beta of 2.21. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company had revenue of $73.47 million during the quarter, compared to analyst estimates of $65.92 million. During the same period in the prior year, the company earned ($0.34) earnings per share. The firm’s revenue was up 357.0% on a year-over-year basis. Analysts predict that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.